Alipogene tiparvovec

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Alipogene tiparvovec
DrugBank Accession Number
DB13521
Background

Alipogene tiparvovec is an adeno-associated viral vector of serotype 1-based gene therapy that delivers the Ser(447)X variant of the human lipoprotein lipase (LPL) gene. It is being investigated for the treatment of lipoprotein lipase (LPL) deficiency.1,2,3,4

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Gene Therapies
Other gene therapies
Synonyms
  • AAV1-LPL S447X
  • AAV1-LPL(S447X)
  • Alipogene tiparvovec
External IDs
  • AMT-011

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Glybera (uniQure N.V.)

Categories

ATC Codes
C10AX10 — Alipogene tiparvovec
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
20OK4AFR4Y
CAS number
929881-05-0

References

General References
  1. Burnett JR, Hooper AJ: Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. Curr Opin Mol Ther. 2009 Dec;11(6):681-91. [Article]
  2. Scott LJ: Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency. Drugs. 2015 Feb;75(2):175-82. doi: 10.1007/s40265-014-0339-9. [Article]
  3. Gaudet D, de Wal J, Tremblay K, Dery S, van Deventer S, Freidig A, Brisson D, Methot J: Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl. 2010 Jun;11(1):55-60. doi: 10.1016/j.atherosclerosissup.2010.03.004. Epub 2010 Apr 27. [Article]
  4. Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, Tremblay G, Tremblay K, de Wal J, Twisk J, van den Bulk N, Sier-Ferreira V, van Deventer S: Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013 Apr;20(4):361-9. doi: 10.1038/gt.2012.43. Epub 2012 Jun 21. [Article]
KEGG Drug
D10843
Wikipedia
Alipogene_tiparvovec

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnTreatmentLPL Deficiency1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at June 23, 2017 20:43 / Updated at June 02, 2023 02:07